Gilead disputes report that its drug flopped in coronavirus trial

(Reuters) - A closely-watched Gilead Sciences Inc experimental antiviral drug failed to help patients with severe COVID-19 in a clinical trial conducted in China, but the drugmaker said the study's results were inconclusive because it was terminated early. Gilead shares fell more than 4% after the data was inadvertently released and first reported by the Financial Times. It comes days after another report detailed rapid recovery in fever and respiratory symptoms in some patients with..